Combination of phospholipase Cε knockdown with GANT61 sensitizes castration‑resistant prostate cancer cells to enzalutamide by suppressing the androgen receptor signaling pathway Corrigendum in /10.3892/or.2022.8426

Sun,Wei; Li,Luo; Du,Zhongbo; Quan,Zhen; Yuan,Mengjuan; Cheng,Honglin; Gao,Yingying; Luo,Chunli; Wu,Xiaohou

doi:10.3892/or.2019.7054

Combination of phospholipase Cε knockdown with GANT61 sensitizes castration‑resistant prostate cancer cells to enzalutamide by suppressing the androgen receptor signaling pathway

Corrigendum in: /10.3892/or.2022.8426

Authors:
- Wei Sun
- Luo Li
- Zhongbo Du
- Zhen Quan
- Mengjuan Yuan
- Honglin Cheng
- Yingying Gao
- Chunli Luo
- Xiaohou Wu
View Affiliations

Affiliations: Department of Urology, The First Affiliated Hospital, Chongqing Medical University, Chongqing 400016, P.R. China, Key Laboratory of Laboratory Medical Diagnostics, Ministry of Education, Department of Laboratory Medicine, Chongqing Medical University, Chongqing 400016, P.R. China, Department of Urology, Affiliated Hospital of North Sichuan Medical College, Nanchong, Sichuan 637000, P.R. China
Published online on: March 7, 2019 https://doi.org/10.3892/or.2019.7054
Pages: 2689-2702
Copyright: © Sun et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Castration‑resistant prostate cancer (CRPC) is a major challenge in the treatment of prostate cancer (PCa). Phospholipase Cε (PLCε), an oncogene, has been found to be involved in the carcinogenesis, tumor proliferation and migration of several types of cancer. The effects, however, of PLCε on CRPC remains unclear. In the present study, the expression of PLCε and glioma‑associated homolog (Gli)‑1/Gli‑2 in benign prostatic hyperplasia (BPH), PCa and CRPC tissues and cells was investigated, and the correlations between PLCε and Gli‑1/Gli‑2 in CRPC tissues and cell lines were further explored. In addition, the effect of PLCε on cell proliferation and invasion was assessed in CRPC cell lines, and the sensitivity of EN‑R and 22RV1 cells to enzalutamide following the downregulation of PLCε expression was determined using lentivirus‑mediated shPLCε and/or treatment with specific Gli inhibitor GANT61. It was found that the PLCε expression was excessively upregulated in the majority of CRPC tissues, and PLCε positivity was linked to poor progression‑free survival (PFS) and overall survival (OS) in patients with PCa. Furthermore, PLCε knockdown significantly suppressed CRPC cell proliferation and invasion. Of note, it was found that PLCε knockdown increased the sensitivity of CRPC cells to enzalutamide in vitro by suppressing androgen receptor (AR) activities via the non‑canonical Hedgehog/Gli‑2 and p‑STAT3 signaling pathways. PLCε knockdown was shown to increase the sensitivity of CRPC cell xenografts to enzalutamide in vivo. Finally, the combination of PLCε knockdown with GANT61 significantly sensitized CRPC cells to enzalutamide. Collectively, the results of the present study suggest that PLCε is a potential therapeutic target for CRPC.

View Figures

View References

1	Siegel R, Ma J, Zou Z and Jemal A: Cancer statistics, 2014. CA Cancer J Clin. 64:9–29. 2014. View Article : Google Scholar : PubMed/NCBI
2	Du LB, Li HZ, Wang XH, Zhu C, Liu QM, Li QL, Li XQ, Shen YZ, Zhang XP, Ying JW, et al: Analysis of cancer incidence in Zhejiang cancer registry in China during 2000 to 2009. Asian Pac J Cancer Prev. 15:5839–5843. 2014. View Article : Google Scholar : PubMed/NCBI
3	Qu M, Ren SC and Sun YH: Current early diagnostic biomarkers of prostate cancer. Asian J Androl. 16:549–554. 2014. View Article : Google Scholar : PubMed/NCBI
4	Liu C, Armstrong C, Zhu Y, Lou W and Gao AC: Niclosamide enhances abiraterone treatment via inhibition of androgen receptor variants in castration resistant prostate cancer. Oncotarget. 7:32210–32220. 2016.PubMed/NCBI
5	Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K, de Wit R, Mulders P, Chi KN, Shore ND, et al: Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 367:1187–1197. 2012. View Article : Google Scholar : PubMed/NCBI
6	Tombal B, Borre M, Rathenborg P, Werbrouck P, Van Poppel H, Heidenreich A, Iversen P, Braeckman J, Heracek J, Baskin-Bey E, et al: Long-term efficacy and safety of enzalutamide monotherapy in hormone-naïve prostate cancer: 1- and 2-year open-label follow-up results. Eur Urol. 68:787–794. 2015. View Article : Google Scholar : PubMed/NCBI
7	Beer TM, Armstrong AJ, Rathkopf DE, Loriot Y, Sternberg CN, Higano CS, Iversen P, Bhattacharya S, Carles J, Chowdhury S, et al: Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med. 371:424–433. 2014. View Article : Google Scholar : PubMed/NCBI
8	Song C, Hu CD, Masago M, Kariyai K, Yamawaki-Kataoka Y, Shibatohge M, Wu D, Satoh T and Kataoka T: Regulation of a novel human phospholipase C, PLCepsilon, through membrane targeting by Ras. J Biol Chem. 276:2752–2757. 2001. View Article : Google Scholar : PubMed/NCBI
9	Bunney TD and Katan M: PLC regulation: Emerging pictures for molecular mechanisms. Trends Biochem Sci. 36:88–96. 2011. View Article : Google Scholar : PubMed/NCBI
10	Bai Y, Edamatsu H, Maeda S, Saito H, Suzuki N, Satoh T and Kataoka T: Crucial role of phospholipase Cepsilon in chemical carcinogen-induced skin tumor development. Cancer Res. 64:8808–8810. 2004. View Article : Google Scholar : PubMed/NCBI
11	Wang LD, Zhou FY, Li XM, Sun LD, Song X, Jin Y, Li JM, Kong GQ, Qi H, Cui J, et al: Genome-wide association study of esophageal squamous cell carcinoma in Chinese subjects identifies susceptibility loci at PLCE1 and C20 or f54. Nat Genet. 42:759–763. 2010. View Article : Google Scholar : PubMed/NCBI
12	Wang X, Fan Y, Du Z, Fan J, Hao Y, Wang J, Wu X and Luo C: Knockdown of phospholipase Cε (PLCε) inhibits cell proliferation via phosphatase and tensin homolog deleted on chromosome 10 (PTEN)/AKT signaling pathway in human prostate cancer. Med Sci Monit. 24:254–263. 2018. View Article : Google Scholar : PubMed/NCBI
13	Wang Y, Wu X, Ou L, Yang X, Wang X, Tang M, Chen E and Luo C: PLCε knockdown inhibits prostate cancer cell proliferation via suppression of Notch signalling and nuclear translocation of the androgen receptor. Cancer Lett. 362:61–69. 2015. View Article : Google Scholar : PubMed/NCBI
14	Buonamici S, Williams J, Morrissey M, Wang A, Guo R, Vattay A, Hsiao K, Yuan J, Green J, Ospina B, et al: Interfering with resistance to smoothened antagonists by inhibition of the PI3K pathway in medulloblastoma. Sci Transl Med. 2:51ra702010. View Article : Google Scholar : PubMed/NCBI
15	Wahid M, Jawed A, Mandal RK, Dar SA, Khan S, Akhter N and Haque S: Vismodegib, itraconazole and sonidegib as hedgehog pathway inhibitors and their relative competencies in the treatment of basal cell carcinomas. Crit Rev Oncol Hematol. 98:235–241. 2016. View Article : Google Scholar : PubMed/NCBI
16	Shigemura K, Huang WC, Li X, Zhau HE, Zhu G, Gotoh A, Fujisawa M, Xie J, Marshall FF and Chung LW: Active sonic hedgehog signaling between androgen independent human prostate cancer cells and normal/benign but not cancer-associated prostate stromal cells. Prostate. 71:1711–1722. 2011. View Article : Google Scholar : PubMed/NCBI
17	Yamamichi F, Shigemura K, Behnsawy HM, Meligy FY, Huang WC, Li X, Yamanaka K, Hanioka K, Miyake H, Tanaka K, et al: Sonic hedgehog and androgen signaling in tumor and stromal compartments drives epithelial-mesenchymal transition in prostate cancer. Scand J Urol. 48:523–532. 2014. View Article : Google Scholar : PubMed/NCBI
18	Behnsawy HM, Shigemura K, Meligy FY, Yamamichi F, Yamashita M, Haung WC, Li X, Miyake H, Tanaka K, Kawabata M, et al: Possible role of sonic hedgehog and epithelial-mesenchymal transition in renal cell cancer progression. Korean J Urol. 54:547–554. 2013. View Article : Google Scholar : PubMed/NCBI
19	Lauth M, Bergstrom A, Shimokawa T and Toftgard R: Inhibition of GLI-mediated transcription and tumor cell growth by small-molecule antagonists. Proc Natl Acad Sci USA. 104:8455–8460. 2007. View Article : Google Scholar : PubMed/NCBI
20	Gonnissen A, Isebaert S and Haustermans K: Hedgehog signaling in prostate cancer and its therapeutic implication. Int J Mol Sci. 14:13979–14007. 2013. View Article : Google Scholar : PubMed/NCBI
21	Karhadkar SS, Bova GS, Abdallah N, Dhara S, Gardner D, Maitra A, Isaacs JT, Berman DM and Beachy PA: Hedgehog signalling in prostate regeneration, neoplasia and metastasis. Nature. 431:707–712. 2004. View Article : Google Scholar : PubMed/NCBI
22	Chen Y, Bieber MM and Teng NN: Hedgehog signaling regulates drug sensitivity by targeting ABC transporters ABCB1 and ABCG2 in epithelial ovarian cancer. Mol Carcinog. 53:625–634. 2014.PubMed/NCBI
23	Sims-Mourtada J, Izzo JG, Ajani J and Chao KS: Sonic Hedgehog promotes multiple drug resistance by regulation of drug transport. Oncogene. 26:5674–5679. 2007. View Article : Google Scholar : PubMed/NCBI
24	Singh S, Chitkara D, Mehrazin R, Behrman SW, Wake RW and Mahato RI: Chemoresistance in prostate cancer cells is regulated by miRNAs and Hedgehog pathway. PLoS One. 7:e400212012. View Article : Google Scholar : PubMed/NCBI
25	Chen M, Feuerstein MA, Levina E, Baghel PS, Carkner RD, Tanner MJ, Shtutman M, Vacherot F, Terry S, de la Taille A and Buttyan R: Hedgehog/Gli supports androgen signaling in androgen deprived and androgen independent prostate cancer cells. Mol Cancer. 9:892010. View Article : Google Scholar : PubMed/NCBI
26	Chen G, Goto Y, Sakamoto R, Tanaka K, Matsubara E, Nakamura M, Zheng H, Lu J, Takayanagi R and Nomura M: GLI1, a crucial mediator of sonic hedgehog signaling in prostate cancer, functions as a negative modulator for androgen receptor. Biochem Biophys Res Commun. 404:809–815. 2011. View Article : Google Scholar : PubMed/NCBI
27	Du Z, Li L, Sun W, Wang X, Zhang Y, Chen Z, Yuan M, Quan Z, Liu N, Hao Y, et al: HepaCAM inhibits the malignant behavior of castration-resistant prostate cancer cells by downregulating Notch signaling and PF-3084014 (a gamma-secretase inhibitor) partly reverses the resistance of refractory prostate cancer to docetaxel and enzalutamide in vitro. Int J Oncol. 53:99–112. 2018.PubMed/NCBI
28	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
29	Gonnissen A, Isebaert S, McKee CM, Dok R, Haustermans K and Muschel R: The hedgehog inhibitor GANT61 sensitizes prostate cancer cells to ionizing radiation both in vitro and in vivo. Oncotarget. 7:84286–84298. 2016. View Article : Google Scholar : PubMed/NCBI
30	Chen Q, Xu R, Zeng C, Lu Q, Huang D, Shi C, Zhang W, Deng L, Yan R, Rao H, et al: Down-regulation of Gli transcription factor leads to the inhibition of migration and invasion of ovarian cancer cells via integrin β4-mediated FAK signaling. PLoS One. 9:e883862014. View Article : Google Scholar : PubMed/NCBI
31	Guerrero J, Alfaro IE, Gomez F, Protter AA and Bernales S: Enzalutamide, an androgen receptor signaling inhibitor, induces tumor regression in a mouse model of castration-resistant prostate cancer. Prostate. 73:1291–1305. 2013. View Article : Google Scholar : PubMed/NCBI
32	Hicks SN, Jezyk MR, Gershburg S, Seifert JP, Harden TK and Sondek J: General and versatile autoinhibition of PLC isozymes. Mol Cell. 31:383–394. 2008. View Article : Google Scholar : PubMed/NCBI
33	Wing MR, Snyder JT, Sondek J and Harden TK: Direct activation of phospholipase C-epsilon by Rho. J Biol Chem. 278:41253–41258. 2003. View Article : Google Scholar : PubMed/NCBI
34	Luo XP: Phospholipase C epsilon-1 inhibits p53 expression in lung cancer. Cell Biochem Funct. 32:294–298. 2014. View Article : Google Scholar : PubMed/NCBI
35	Abnet CC, Freedman ND, Hu N, Wang Z, Yu K, Shu XO, Yuan JM, Zheng W, Dawsey SM, Dong LM, et al: A shared susceptibility locus in PLCE1 at 10q23 for gastric adenocarcinoma and esophageal squamous cell carcinoma. Nat Genet. 42:764–767. 2010. View Article : Google Scholar : PubMed/NCBI
36	Smrcka AV, Brown JH and Holz GG: Role of phospholipase Cε in physiological phosphoinositide signaling networks. Cell Signal. 24:1333–1343. 2012. View Article : Google Scholar : PubMed/NCBI
37	Du HF, Ou LP, Song XD, Fan YR, Yang X, Tan B, Quan Z, Luo CL and Wu XH: Nuclear factor-kappa B signaling pathway is involved in phospholipase Cepsilon-regulated proliferation in human renal cell carcinoma cells. Mol Cell Biochem. 389:265–275. 2014. View Article : Google Scholar : PubMed/NCBI
38	Yang X, Ou L, Tang M, Wang Y, Wang X, Chen E, Diao J, Wu X and Luo C: Knockdown of PLCepsilon inhibits inflammatory cytokine release via STAT3 phosphorylation in human bladder cancer cells. Tumour Biol. 36:9723–9732. 2015. View Article : Google Scholar : PubMed/NCBI
39	Sharp A, Welti J, Blagg J and de Bono JS: Targeting androgen receptor aberrations in castration-resistant prostate cancer. Clin Cancer Res. 22:4280–4282. 2016. View Article : Google Scholar : PubMed/NCBI
40	Ardiani A, Gameiro SR, Kwilas AR, Donahue RN and Hodge JW: Androgen deprivation therapy sensitizes prostate cancer cells to T-cell killing through androgen receptor dependent modulation of the apoptotic pathway. Oncotarget. 5:9335–9348. 2014. View Article : Google Scholar : PubMed/NCBI
41	Tran C, Ouk S, Clegg NJ, Chen Y, Watson PA, Arora V, Wongvipat J, Smith-Jones PM, Yoo D, Kwon A, et al: Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science. 324:787–790. 2009. View Article : Google Scholar : PubMed/NCBI
42	Gonnissen A, Isebaert S and Haustermans K: Targeting the Hedgehog signaling pathway in cancer: Beyond smoothened. Oncotarget. 6:13899–13913. 2015. View Article : Google Scholar : PubMed/NCBI
43	Tang X, Deng L, Chen Q, Wang Y, Xu R, Shi C, Shao J, Hu G, Gao M, Rao H, et al: Inhibition of Hedgehog signaling pathway impedes cancer cell proliferation by promotion of autophagy. Eur J Cell Biol. 94:223–233. 2015. View Article : Google Scholar : PubMed/NCBI
44	Nguyen HG, Yang JC, Kung HJ, Shi XB, Tilki D, Lara PN Jr, DeVere White RW, Gao AC and Evans CP: Targeting autophagy overcomes enzalutamide resistance in castration-resistant prostate cancer cells and improves therapeutic response in a xenograft model. Oncogene. 33:4521–4530. 2014. View Article : Google Scholar : PubMed/NCBI